[1]WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB):2010 global report on surveillance and response. 2010.WHO/HTM/TB/2010.3. 2010[2013-03-29]. http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf, 2010.[2]Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis, 2010, 10 (9):621-629.[3]Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2004,169 (10):1103-1109.[4]甄伟, 石大伟, 赵玉玲, 等. 耐多药结核分枝杆菌异烟肼耐药相关基因katG突变分析. 中国防痨杂志, 2013, 35(3): 207-209.[5]崔运勇, 王峰, 刘小立, 等. 深圳市耐多药结核分枝杆菌流行株耐药基因序列分析. 中国防痨杂志, 2011, 33(5): 257-262.[6]Imperiale BR, Cataldi AA, Morcillo NS. Rapid detection of multidrug-resistant Mycobacterium tuberculosis by multiplex allele-specific polymerase chain reaction. Int J Tuberc Lung Dis, 2011, 15 (4):496-501.[7]中国防痨协会. 结核病诊断细菌学检验规程. 中国防痨杂志, 1996,18 (1): 28-31.[8]World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis-4th ed.WHO/HTM/TB/2009.422. Geneva: World Health Organization, 2009.[9]Chen J, Tsolaki AG, Shen X, et al. Deletion-targeted multiplex PCR (DTM-PCR) for identification of Beijing/W genotypes of Mycobacterium tuberculosis. Tuberculosis (Edinb), 2007, 87 (5):446-449.[10]Evans J, Segal H. Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J Antimicrob Chemother, 2010, 65 (5): 897-900.[11]Almeida Da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother, 2011, 66 (7): 1417-1430.[12]Lau RW, Ho PL, Kao RY, et al. Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother, 2011, 55 (2):608-614.[13]Xu P, Li X, Zhao M, et al. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother, 2009, 53 (7):3170-3172.[14]Duong DA, Nguyen TH, Nguyen TN, et al. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob Agents Chemother, 2009, 53 (11):4835-4839.[15]马慧, 胡屹, 蒋伟利, 等. 中国东部农村地区结核分枝杆菌北京基因型菌株的成簇性及耐药特征研究. 中华结核和呼吸杂志, 2011,34(6): 447-450.[16]Nhu NT, Lan NT, Phuong NT, et al. Association of streptomycin resistance mutations with level of drug resistance and Mycobacterium tuberculosis genotypes. Int J Tuberc Lung Dis, 2012, 16 (4): 527-531.[17]Qian L, Abe C, Lin TP, et al. rpoB genotypes of Mycobacterium tuberculosis Beijing family isolates from East Asian countries. J Clin Microbiol, 2002, 40 (3):1091-1094.[18]Zhou A, Nawaz M, Duan Y, et al. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates from Xi’an, China. Microb Drug Resist, 2011, 7 (2): 275-281.[19]金嘉琳,张文宏,胡忠义,等. 等位基因特异性多重聚合酶链反应方法用于快速检测结核分枝杆菌利福平耐药株. 中华结核和呼吸杂志, 2005,28 (9): 623-625.[20]夏强, 赵丽丽, 刘志广, 等. 等位基因特异性多重PCR快速检测结核分枝杆菌喹诺酮耐药性的初步研究. 医学研究杂志, 2011,40(4): 31-34.[21]Blaschitz M, Hasanacevic D, Hufnagl P, et al. Real-time PCR for single-nucleotide polymorphism detection in the 16S rRNA gene as an indicator for extensive drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother, 2011, 66 (6):1243-1246.[22]Tho DQ, Ha DT, Duy PM, et al. Comparison of MAS-PCR and Geno Type MTBDR assay for the detection of rifampicin-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis, 2008, 12 (11):1306-1312.[23]Hanekom M, Gey van Pittius NC, McEvoy C, et al. Mycobacterium tuberculosis Beijing genotype: A template for success. Tuberculosis (Edinb), 2011, 91 (6):510-523.[24]张治国, 欧喜超, 孙倩, 等. 利福平耐药实时荧光定量核酸扩增技术检测痰标本中结核分枝杆菌及其耐药性的研究. 中国防痨杂志, 2013, 35(1): 13-16. |